Clinical Trial Update: Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes. [Phase 3]

View source ↗

Summary

Phase 3 bioequivalence study with clinical endpoint comparing bimatoprost ophthalmic solution 0.01% to LUMIGAN in chronic open-angle glaucoma or ocular hyperten…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glaucoma Open-angle
• Ocular Hypertension

Drugs mentioned

• Bimatoprost Ophthalmic Solution 0.01% (bimatoprost)
• Lumigan (bimatoprost)

Snippet

Sponsor: Amneal Pharmaceuticals, LLC | Conditions: Glaucoma, Open-Angle, Ocular Hypertension | Phase 3 | Status: RECRUITING